Titan Medical Stock

When is Sport going to launch? It seems like we've heard about this product forever but nothing has come to market. Smoke & mirrors IMO.

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

One of the biggest challenges for the entire space is that there is very little clinical data showing superior outcomes of robotic surgery vs. standard laparoscopy. At the present time, using the robot on a procedure does not generate any additional reimbursement for the hospital or surgeon.

If robotic surgery fails to deliver significantly better outcomes I don't see how insurance companies will ever pay more for it. Take that with the pending shift to a value-based care model and increased competition, and its a recipe for fewer robotic procedures to go around and lower margins for everybody.

With literally billions sunk into the myriad of systems that are still years from commercial launch, I have a hard time visualizing a path to profitability for most of them.

This was on the TRXC board on StockTwits this morning and does a nice job reviewing the future landscape of robotic surgery companies.

What's Next for TransEnterix after Senhance's FDA Clearance | Medtechy

In typical FDA fashion, TransEnterix received their FDA clearance letter late Friday afternoon for their Senhance surgical robot which was very welcomed by…

post

I don't disagree that there will only be 2 or 3 players in the market but because Intuitive has really been the only player for so long, I think new ideas and technologies will still come. At some point, a player like Intuitive, JNJ or MDT will acquire one of the platforms from a smaller player. I don't want to throw names out there because Intuitive doesn't have much of a need to acquire TRXC. TRXC has some cool features but there is nothing that Intuitive isn't already developing. Titan is a much tougher read because their development has taken so long. A $4-$5 price for TRXC hasn't come close to irrational exuberance. Same with Titan. These companies just need to perform and let the market decide if they get to stick around. As Titan has learned, developing a surgical robot is hard and not many companies have the time, stomach or money to develop one.

One of the biggest challenges for the entire space is that there is very little clinical data showing superior outcomes of robotic surgery vs. standard laparoscopy. At the present time, using the robot on a procedure does not generate any additional reimbursement for the hospital or surgeon.

If robotic surgery fails to deliver significantly better outcomes I don't see how insurance companies will ever pay more for it. Take that with the pending shift to a value-based care model and increased competition, and its a recipe for fewer robotic procedures to go around and lower margins for everybody.

With literally billions sunk into the myriad of systems that are still years from commercial launch, I have a hard time visualizing a path to profitability for most of them.

post

Robotic surgery per se is not a bubble, but it does seem like there is some irrational exuberance around the multitude of abdominal/thoracic platforms currently in development. I just don't see how more than two or three systems will compete in the space long-term, and that includes the 8000 pound gorilla that is already in the room.

I don't disagree that there will only be 2 or 3 players in the market but because Intuitive has really been the only player for so long, I think new ideas and technologies will still come. At some point, a player like Intuitive, JNJ or MDT will acquire one of the platforms from a smaller player. I don't want to throw names out there because Intuitive doesn't have much of a need to acquire TRXC. TRXC has some cool features but there is nothing that Intuitive isn't already developing. Titan is a much tougher read because their development has taken so long. A $4-$5 price for TRXC hasn't come close to irrational exuberance. Same with Titan. These companies just need to perform and let the market decide if they get to stick around. As Titan has learned, developing a surgical robot is hard and not many companies have the time, stomach or money to develop one.

post

The robotic surgery market is NOT in a bubble - not even CLOSE to one.

Robotic surgery per se is not a bubble, but it does seem like there is some irrational exuberance around the multitude of abdominal/thoracic platforms currently in development. I just don't see how more than two or three systems will compete in the space long-term, and that includes the 8000 pound gorilla that is already in the room.

post

**** Titan. At this point, I have no choice but to ride this nag all the way to the finish, but I'm not optimistic. If their tech was worth a ****, one of the Big Boys would've snapped it up already. The entire robotic surgery market is a bubble.

The robotic surgery market is NOT in a bubble - not even CLOSE to one.

Show Language

post

Titan is a painful company to own stock in. Now they just completed a reverse split which helps the stock appear like it is worth more than it is. Except the company is literally the same value at $8 as it was yesterday at .20. The smart money doesn't fall for this trick and only fools individual investors. Titan needs SPORT to get FDA clearance quickly. Reverse splits don't usually work out either. Be careful.

**** Titan. At this point, I have no choice but to ride this nag all the way to the finish, but I'm not optimistic. If their tech was worth a ****, one of the Big Boys would've snapped it up already. The entire robotic surgery market is a bubble.

Show Language

post

Titan is a painful company to own stock in. Now they just completed a reverse split which helps the stock appear like it is worth more than it is. Except the company is literally the same value at $8 as it was yesterday at .20. The smart money doesn't fall for this trick and only fools individual investors. Titan needs SPORT to get FDA clearance quickly. Reverse splits don't usually work out either. Be careful.

post

Updated videos of SPORT in a pre-clinical setting.

I guess thanks for posting. Lots of fancy new videos yet they have a .25 stock. The dilution will be unrecoverable by the time they hit the market.

post

Great video showing a single port urological procedure performed with SPORT --


post

The sad thing is most of these investors in TRXC don't realize that Senhance is an older, failed product that didn't sell in Europe. SurgiBot was their opportunity and they missed on it.

Actually the sad thing is Titan has never, and possibly will never, get a product to market....how long has SPORT been in development???

post

First use at Columbia so that's a good thing. I feel like SPORT will be a winner once it is approved. They will actually sell units unlike TransEnterix with that repackaged ALF-X.

The sad thing is most of these investors in TRXC don't realize that Senhance is an older, failed product that didn't sell in Europe. SurgiBot was their opportunity and they missed on it.

post

Loading...


Load More

Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.